临床分离的美罗培南和环丙沙星共同耐药的铜绿假单胞菌耐药机制的研究

doi:10.3969/j.issn.1673-8640.2014.06.016

检验医学 ›› 2014, Vol. 29 ›› Issue (6): 646-650.DOI: 10.3969/j.issn.1673-8640.2014.06.016

临床分离的美罗培南和环丙沙星共同耐药的铜绿假单胞菌耐药机制的研究

张国栋¹,王莹²,朱红胜¹

1. 南京医科大学附属苏州医院,苏州市立医院(东区)检验科,江苏苏州 215001;
2. 南京市浦口区疾病预防控制中心,江苏南京 210031

收稿日期:2013-07-20 出版日期:2014-06-30 发布日期:2014-06-23
通讯作者: 朱红胜, 联系电话:0512-62364338。
作者简介:张国栋,男,1981年生,学士,主管技师,主要从事临床微生物检验工作。

Research on the drug resistance mechanisms of meropenem and ciprofloxacin in clinical isolates of Pseudomonas aeruginosa

ZHANG Guodong¹, WANG Ying², ZHU Hongsheng¹

1. Department of Clinical Laboratory, the Affiliated Suzhou Municipal Hospital(East-Section) of Nanjing Medical University, Jiangsu Suzhou 215001, China;
2. Pukou District Center for Disease Control and Prevention, Jiangsu Nanjing 210031, China

Received:2013-07-20 Online:2014-06-30 Published:2014-06-23

摘要/Abstract

摘要： 目的探讨临床分离的对美罗培南和环丙沙星均耐药的铜绿假单胞菌的耐药机制。方法收集经VITEK-2 Compact微生物分析系统检测为美罗培南和环丙沙星耐药的铜绿假单胞菌30株,琼脂稀释法复查最小抑菌浓度(MIC)值。改良三维试验检测碳青霉烯酶,聚合酶链反应(PCR)扩增耐药基因,逆转录PCR 分析细菌外排系统表达情况。结果琼脂稀释法与VITEK-2 Compact微生物分析系统检测结果相同。所有菌株均未产碳青霉烯酶,PCR扩增测序未发现基因改变,逆转录PCR检测外排系统发现以mexX和mexC基因表达增加为主,其调控基因扩增测序发现4株mexC过度表达的调控基因nfxB Gly→Val(GGC→GTC),6株mexX过度表达的调控基因mexZ Val→Gly(CTG→CAG)。结论外排系统调控基因突变而引起的外排系统MexXY-OprM和MexCD-OprJ过度表达是引起美罗培南和环丙沙星耐药的主要原因。

关键词: 铜绿假单胞菌, 耐药机制, 美罗培南, 环丙沙星, 外排系统

Abstract: Objective To investigate the drug resistance mechanisms of both meropenem and ciprofloxacin in clinical isolates of Pseudomonas aeruginosa. Methods A total of 30 isolates of Pseudomonas aeruginosa which had been tested resistance to both meropenem and ciprofloxacin by VITEK-2 Compact were collected. Agar dilution method was used to reexamine the minimal inhibitory concentrations (MIC) of meropenem and ciprofloxacin. Carbapenemases were detected by modified three-dimensional test. The resistance genes were analyzed by polymerase chain reaction (PCR) amplification. The expression of efflux systems was analyzed by reverse transcription PCR. Results The same results were showed between agar dilution method and VITEK-2 Compact. Carbapenemases were not detected by modified three-dimensional test. The overexpression ofmexX and mexC genes were detected by reverse transcription PCR. The sequencing of regulatory genes showed that there were 4 isolates which the Gly(GGC) of nfxB was substitute for Val(GTC) and 6 isolates which the Val(CTG)of mexZ was substitute for Gly (CAG). Conclusions The overexpression of the MexXY-OprM and MexCD-OprJ efflux system, due to the mutation of regulatory genes of efflux system, is contributed to the drug resistance to both meropenem and ciprofloxacin of Pseudomonas aeruginosa.

Key words: Pseudomonas aeruginosa, Drug resistance mechanism, Meropenem, Ciprofloxacin, Efflux system

中图分类号:

R446.5

张国栋,王莹,朱红胜. 临床分离的美罗培南和环丙沙星共同耐药的铜绿假单胞菌耐药机制的研究[J]. 检验医学, 2014, 29(6): 646-650.

ZHANG Guodong, WANG Ying, ZHU Hongsheng. Research on the drug resistance mechanisms of meropenem and ciprofloxacin in clinical isolates of Pseudomonas aeruginosa[J]. , 2014, 29(6): 646-650.

参考文献

[1] Rodríguez-Martínez JM, Poirel L, Nordmann P. Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa[J] . Antimicrob Agents Chemother, 2009,53(11):4783-4788.
[2] Pasca MR, Dalla Valle C, De Jesus Lopes Ribeiro AL,et al. Evaluation of fluoroquinolone resistance mechanisms in Pseudomonas aeruginosa multidrug resistance clinical isolates[J] . Microb Drug Resist, 2012,18(1):23-32.
[3] 邵海枫,刘金波,张小卫,等.用于三维试验的最适酶抑制剂浓度探讨[J] .临床检验杂志,2003,21(6):352-353.
[4] Coban AY, Ekinci B, Durupinar B. A multidrug efflux pump inhibitor reduces fluoroquinolone resistance in Pseudomonas aeruginosa isolates[J] . Chemotherapy, 2004, 50(1): 22-26.
[5] Valdezate S, Vindel A, Echeita A, et al. Topoisomerase Ⅱ and Ⅳ quinolone resistance-determining regions in Stenotrophomonas maltophilia clinical isolates with different levels of quinolone susceptibility[J] . Antimicrob Agents Chemother, 2002, 46(4): 665-671.
[6] Linares JF, López JA, Camafeita E,et al. Overexpression of the multidrug efflux pumps MexCD-OprJ and MexEF-OprN is associated with a reduction of type Ⅲ secretion in Pseudomonas aeruginosa[J] . J Bacteriol,2005,187(4):1384-1391.
[7] Hammami S, Ghozzi R, Burghoffer B, et al. Mechanisms of carbapenem resistance in non-metallo-beta-lactamase-producing clinical isolates of Pseudomonas aeruginosa from a Tunisian hospital[J] . Pathol Biol (Paris),2009,57(7-8):530-535.
[8] Campo Esquisabel AB, Rodríguez MC, Campo-Sosa AO,et al .Mechanisms of resistance in clinical isolates of Pseudomonas aeruginosa less susceptible to cefepime than to ceftazidime[J] . Clin Microbiol Infect, 2011,17(12): 1817-1822.
[9] Higgins PG, Fluit AC, Milatovic D, et al. Mutations in GyrA, ParC, MexR and NfxB in clinical isolates of Pseudomonas aeruginosa[J] . Int J Antimicrob Agents, 2003, 21(5): 409-413.
[10] 曾章锐,邵海枫,王卫萍,等. 头孢菌素敏感或中介的铜绿假单胞菌对亚胺培南耐药机制的研究[J] . 临床检验杂志,2013,31(1):24-27.
[11] Levine C, Hiasa H, Marians KJ. DNA gyrase and topoisomerase Ⅳ: biochemical activities, physiological roles during chromosome replication, and drug sensitivities[J] . Biochim Biophys Acta, 1998,1400(1-3):29-43.
[12] Hocquet D, Nordmann P, El Garch F,et al. Involvement of the MexXY-OprM efflux system in emergence of cefepime resistance in clinical strains of Pseudomonas aeruginosa[J] . Antimicrob Agents Chemother, 2006,50(4):1347-1351.
[13] Masuda N, Sakagawa E, Ohya S,et al. Substrate specificities of MexAB-OprM, MexCD-OprJ, and MexXY-oprM efflux pumps in Pseudomonas aeruginosa[J] . Antimicrob Agents Chemother, 2000,44(12):3322-3327.
[14] Kriengkauykiat J, Porter E, Lomovskaya O, et al. Use of an efflux pump inhibitor to determine the prevalence of efflux pump-mediated fluoroquinolone resistance and multidrug resistance in Pseudomonas aeruginosa[J] . Antimicrob Agents Chemother, 2005, 49(2): 565-570.

[1]	费冰, 刘莹, 任彦颖, 郭梦雨, 刘心伟, 刘冬梅, 李永伟. 环二鸟苷酸调控铜绿假单胞菌生物被膜研究进展[J]. 检验医学, 2023, 38(2): 186-189.
[2]	陈庆, 徐蓉, 孙景勇. 上海地区支气管扩张症患者铜绿假单胞菌耐药机制和分子流行病学特征[J]. 检验医学, 2023, 38(11): 1020-1025.
[3]	翟莎娜, 孙清海, 余永武, 叶芳, 刘茂东. 万古霉素联合美罗培南对PDRP患者疗效及血清TNF-α、PCT、IL-6水平和腹膜液WBC计数的影响[J]. 检验医学, 2022, 37(4): 360-364.
[4]	王立新, 苏云福, 王毅. 临床病原菌磷霉素耐药机制研究进展[J]. 检验医学, 2022, 37(10): 993-997.
[5]	王琼, 王新, 陈晓敏, 张慧峰. 美罗培南致继发性血小板增多症1例报道[J]. 检验医学, 2021, 36(1): 117-118.
[6]	李婵婵, 王茹, 罗文英. 铜绿假单胞菌转录因子PsrA全局调控研究进展[J]. 检验医学, 2020, 35(8): 832-836.
[7]	王姜琳, 孙杰, 杨慧健, 王冰洁, 潘芬, 张泓. 儿童耐氨苄西林流感嗜血杆菌耐药机制及同源性研究[J]. 检验医学, 2020, 35(6): 513-518.
[8]	钟峰, 冯艺, 张晶晶, 许岩, 方咏梅, 陶秀彬, 吴竞. 替加环素联合亚胺培南对黏液型铜绿假单胞菌的体外抗菌活性及生物膜抑制作用分析[J]. 检验医学, 2020, 35(6): 519-523.
[9]	张心宇, 杜雪飞, 邹桂玲, 姜晓峰. 鲍曼不动杆菌对替加环素耐药机制研究进展[J]. 检验医学, 2019, 34(7): 656-660.
[10]	毛磊, 王炜, 苏建荣. 北京市某医院354株铜绿假单胞菌分布及耐药情况分析[J]. 检验医学, 2019, 34(6): 502-505.
[11]	李巍, 艾芙琪, 马逸珉, 王蓓, 田月如. 携带bla_NDM-1碳青霉烯类耐药雷极普罗威登斯菌耐药机制研究[J]. 检验医学, 2019, 34(1): 67-70.
[12]	范雪梅. 亚抑菌浓度阿奇霉素与妥布霉素联合应用对铜绿假单胞菌疗效的分析[J]. 检验医学, 2017, 32(10): 879-882.
[13]	赵虎. 深部真菌的耐药性及其耐药机制研究[J]. 检验医学, 2016, 31(9): 735-738.
[14]	黄秋兰, 范德平, 高守霞, 刘红绸, 薛娜丽, 倪语星. Ⅰ类整合子对铜绿假单胞菌亚胺培南耐药诊断价值的Meta分析[J]. 检验医学, 2016, 31(6): 491-498.
[15]	徐伟红, 徐斌, 姚怡婷, 黄明敏, 张骏, 赵虎. 铜绿假单胞菌产AmpC β-内酰胺酶及外膜孔蛋白OprD₂基因缺失分析[J]. 检验医学, 2016, 31(4): 309-313.

临床分离的美罗培南和环丙沙星共同耐药的铜绿假单胞菌耐药机制的研究

Research on the drug resistance mechanisms of meropenem and ciprofloxacin in clinical isolates of Pseudomonas aeruginosa

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics